9/23
08:46 am
cccc
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
9/23
08:43 am
cccc
Rating for CCCC
Medium
Report
Rating for CCCC
9/23
08:43 am
cccc
Rating for CCCC
Medium
Report
Rating for CCCC
9/23
06:47 am
cccc
Rating for CCCC
Medium
Report
Rating for CCCC
9/23
06:47 am
cccc
Rating for CCCC
Medium
Report
Rating for CCCC
9/22
08:40 am
cccc
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $6.00 price target on the stock.
High
Report
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $6.00 price target on the stock.
9/22
08:40 am
cccc
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $6.00 price target on the stock.
High
Report
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $6.00 price target on the stock.
9/22
08:21 am
cccc
Rating for CCCC
High
Report
Rating for CCCC
9/22
08:05 am
cccc
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
High
Report
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
9/18
06:43 am
cccc
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
9/17
08:05 am
cccc
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $8.00 price target on the stock.
Low
Report
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $8.00 price target on the stock.
9/17
06:47 am
cccc
Rating for CCCC
Low
Report
Rating for CCCC
9/17
06:47 am
cccc
Rating for CCCC
Low
Report
Rating for CCCC
9/16
04:46 pm
cccc
C4 Therapeutics initiated with an Overweight at Barclays
Low
Report
C4 Therapeutics initiated with an Overweight at Barclays
9/16
04:46 pm
cccc
C4 Therapeutics initiated with an Overweight at Barclays
Low
Report
C4 Therapeutics initiated with an Overweight at Barclays
9/16
04:16 pm
cccc
C4 Therapeutics initiated with an Overweight at Barclays
Medium
Report
C4 Therapeutics initiated with an Overweight at Barclays
9/16
04:16 pm
cccc
C4 Therapeutics initiated with an Overweight at Barclays
Medium
Report
C4 Therapeutics initiated with an Overweight at Barclays
9/15
09:37 am
cccc
Rating for CCCC
High
Report
Rating for CCCC
9/15
08:02 am
cccc
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Stephens from an "equal weight" rating to an "overweight" rating. They now have a $6.00 price target on the stock.
High
Report
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Stephens from an "equal weight" rating to an "overweight" rating. They now have a $6.00 price target on the stock.
9/15
08:02 am
cccc
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Stephens from an "equal weight" rating to an "overweight" rating. They now have a $6.00 price target on the stock.
High
Report
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Stephens from an "equal weight" rating to an "overweight" rating. They now have a $6.00 price target on the stock.
9/15
06:23 am
cccc
C4 Therapeutics upgraded to Overweight from Equal Weight at Stephens
High
Report
C4 Therapeutics upgraded to Overweight from Equal Weight at Stephens
9/15
06:23 am
cccc
C4 Therapeutics upgraded to Overweight from Equal Weight at Stephens
High
Report
C4 Therapeutics upgraded to Overweight from Equal Weight at Stephens
9/9
05:55 am
cccc
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Low
Report
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
9/9
05:55 am
cccc
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Low
Report
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Guggenheim to a "strong-buy" rating.